
Conference Coverage
about 1 month ago
Cefiderocol Shows Activity Against Difficult-to-Treat Pathogensabout 2 months ago
Does Where People Live Affect Antibiotic Prescribing Practices?about 2 months ago
Considering Alternatives to Vancomycin for MRSALatest Content

Jan 04, 2026 | News
Destruction from Within, Resistance from Without

Top Infectious Disease News Stories Week of December 27 - January 2
Jan 03, 2026

Increasing PPE Standards to Protect Patients, Healthcare Workers
Jan 02, 2026

US Influenza Activity Accelerates Into the New Year as Hospitalizations Rise
Jan 02, 2026

CDC's Latest Hepatitis B Vaccine Guidance Serves as Example for Future Federal Vaccine Policy
Dec 31, 2025

Advertisement
Shorts

0:39
Challenges of Acquiring Phage Therapy
2 months ago
by
Ashlan Kunz Coyne, PharmD, MPH(+1 more)

0:48
Building Parents' Trust About Childhood Vaccines
2 months ago
by
Ruth Lynfield, MD(+1 more)

0:14
A Monoclonal Antibody as a COVID-19 Alternative
2 months ago
by
Robert Allen, PhD(+1 more)

0:36
Vaccines as a Secondary Strategy in the Fight Against Antimicrobial Resistance
3 months ago
by
Barry Kreiswirth, PhD(+1 more)

0:36
The Center for Discovery and Innovation’s Commitment to Fungal Diagnostics and Treatment
3 months ago
by
David Perlin, PhD(+1 more)

0:41
Kevin Ault, MD on ACIP Shared Decision-Making, Informed Consent, and Vaccine Policy
3 months ago
by
Kevin Ault, MD(+1 more)

0:52
Adoption of Rapid Diagnostic Tools, Susceptibility Testing for Gram-Negative Infections
3 months ago
by
Rodney E. Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc; and Ryan P. McNamara, PhD(+1 more)

0:26
Why Intestinal Antibodies Are Key to Beating Norovirus Infection
3 months ago
by
Sean N Tucker, PhD(+1 more)

0:22
Examining Chronic Chikungunya and Potential Clues to Rheumatologic Symptoms
3 months ago
by
Daniela Weiskopf, PhD(+1 more)

0:28
Clinical Considerations for Using Newer Antibiotics for Gram-Negative Infections
3 months ago
by
Ryan K. Shields, PharmD, MS(+1 more)
Podcasts
Videos
Contagion Digital Edition

A series of politically driven actions in 2025—including defunding mRNA research, dismantling vaccine advisory bodies, and restricting CDC recommendations—has undermined US vaccine access and pandemic preparedness, but professional societies and some states are stepping in to preserve evidence-based public health.

The NARROWS framework, developed within the IDSA Core Antimicrobial Stewardship Curriculum, provides a structured, behaviorally informed approach to communication that helps stewardship teams address the social, emotional, and cultural factors influencing prescribing decisions in order to optimize antimicrobial use and combat resistance.

Stenotrophomonas maltophilia is an opportunistic, multidrug-resistant pathogen that poses significant treatment challenges due to its complex resistance mechanisms, limited therapeutic options, and high mortality rates among vulnerable patients.

This review highlights how people living with HIV are living longer due to antiretroviral therapy but face unique age-related health challenges, including cardiovascular disease, metabolic syndrome, renal dysfunction, neurocognitive decline, immunosenescence, bone loss, and frailty, requiring tailored screening and management strategies.

Biosurveillance is an essential early warning system for detecting and responding to infectious disease threats, helping to prevent localized cases from becoming widespread outbreaks or pandemics. Despite its proven value during crises such as COVID-19, biosurveillance programs often suffer from inconsistent funding and support, underscoring the urgent need for sustained investment and integration into public health infrastructure.

Clinical trial and real-world data, including the PROVE study, support its role as an effective and carbapenem-sparing therapy for serious infections, though outcomes vary depending on pathogen and infection type.

Doxycycline postexposure prophylaxis is associated with emerging tetracycline resistance in Neisseria gonorrhoeae and commensal organisms, highlighting the need for cautious, targeted use.

A recent literature review describes the current state of artificial intelligence tools for guiding antimicrobial therapy. Are you ready for change?
































































































































